Pfizer deals extend patent life for a top-selling rare disease drug

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.

By PharmaVoice · Apr 30, 2026 · via PharmaVoice

Pfizer deals extend patent life for a top-selling rare disease drug

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.